Accuray Stock Forecast, Price & News

Accuray (NASDAQ:ARAY) Frequently Asked Questions

Is Accuray a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray or view top-rated stocks.

What stocks does MarketBeat like better than Accuray?

Wall Street analysts have given Accuray a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accuray wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Accuray.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) announced its earnings results on Tuesday, August, 10th. The medical equipment provider reported ($0.01) EPS for the quarter, beating the Zacks' consensus estimate of ($0.02) by $0.01. The medical equipment provider had revenue of $110.94 million for the quarter, compared to analysts' expectations of $101.65 million. Accuray had a negative net margin of 1.59% and a positive trailing twelve-month return on equity of 4.91%. During the same period last year, the company earned ($0.01) EPS.
View Accuray's earnings history.

How has Accuray's stock price been impacted by COVID-19?

Accuray's stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARAY stock has increased by 71.4% and is now trading at $3.89.
View which stocks have been most impacted by COVID-19.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2022 earnings guidance on Wednesday, September, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $410 million-$420 million, compared to the consensus revenue estimate of $418.68 million.

Who are Accuray's key executives?

Accuray's management team includes the following people:

• Joshua H. Levine, Chief Executive Officer & Director (LinkedIn Profile)
• Suzanne C. Winter, President
• Michael Hoge, Senior Vice President-Global Operations
• Jean-Philippe Pignol, Senior VP, Chief Medical & Technology Officer
• Jesse Chew, Secretary, Senior VP & General Counsel

What is Joshua Levine's approval rating as Accuray's CEO?

78 employees have rated Accuray CEO Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among Accuray's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Accuray's key competitors?

Some companies that are related to Accuray include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of ARAY's competitors.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.49%), Neuberger Berman Group LLC (5.49%), Vanguard Group Inc. (5.45%), Renaissance Technologies LLC (3.98%), State Street Corp (2.83%) and Dimensional Fund Advisors LP (2.67%). Company insiders that own Accuray stock include Andrew J Kirkpatrick, Byron C Scott, Jesse Chew, Joseph E Whitters, Joseph E Whitters, Joshua Levine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends for Accuray.

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Millennium Management LLC, BlackRock Inc., JPMorgan Chase & Co., AQR Capital Management LLC, Squarepoint Ops LLC, Panagora Asset Management Inc., and Neuberger Berman Group LLC. Company insiders that have sold Accuray company stock in the last year include Jesse Chew, Joshua Levine, Shigeyuki Hamamatsu, and Suzanne C Winter.
View insider buying and selling activity for Accuray or view top insider-selling stocks.

Which major investors are buying Accuray stock?

ARAY stock was acquired by a variety of institutional investors in the last quarter, including Harbert Fund Advisors Inc., State Street Corp, Vanguard Group Inc., HealthInvest Partners AB, Russell Investments Group Ltd., Tocqueville Asset Management L.P., Cowen Prime Advisors LLC, and Renaissance Technologies LLC. Company insiders that have bought Accuray stock in the last two years include Byron C Scott, Joseph E Whitters, and Joshua Levine.
View insider buying and selling activity for Accuray or or view top insider-buying stocks.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $3.89.

How much money does Accuray make?

Accuray has a market capitalization of $353.32 million and generates $396.29 million in revenue each year. The medical equipment provider earns $-6,310,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How many employees does Accuray have?

Accuray employs 932 workers across the globe.

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.

When was Accuray founded?

Accuray was founded in 1990.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

Where are Accuray's headquarters?

Accuray is headquartered at 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at (408) 716-4600 or via email at [email protected].